Table 2.
Characteristics of the included studies for dose–response meta‐analysis for length of surgery and pressure ulcer risk
| First author, year, country, study design, NOS SRPU definition (stage), SRPU total incidence | LOS category (min) | SRPU (+) | SRPU (−) | SRPU incidence | Odds ratio (95% CI) |
|---|---|---|---|---|---|
| Shen, 2015 6 | <120 | 2 | 74 | 2·6% | 1·0[ref.] |
| China | 120‐180 | 5 | 27 | 15·6% | 6·851(1·025–74·392) |
| Retrospective cohort | 180‐240 | 13 | 65 | 16·7% | 7·4(1·568–69·209) |
| 8 | 240‐300 | 12 | 42 | 22·2% | 10·571(2·16–99·986) |
| I–IV | 300‐360 | 10 | 13 | 43·5% | 28·462(4·98–280·784) |
| 16·4%· | 360‐600 | 1 | 8 | 11·1% | 4·625(0·07–95·572) |
| >600 | 2 | 1 | 66·7% | 74(2·277–4411·217) | |
| Aronovitch, 1999 17 | <180 | 26 | 423 | 5·8% | 1·0[ref.] |
| USA | 180‐240 | 27 | 276 | 8·9% | 1·592(0·873–2·903) |
| Retrospective survey | 240‐300 | 20 | 182 | 9·9% | 1·788(0·92–3·422) |
| 7 | 300‐360 | 6 | 75 | 7·4% | 1·302(0·423–3·377) |
| I–IV | 360‐420 | 3 | 34 | 8·1% | 1·356(0·265–5·058) |
| 8·1% | 420‐480 | 2 | 19 | 9·5% | 1·713(0·184–7·743) |
| >480 | 8 | 15 | 34·8% | 8·677(2·883–24·059) |